Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Other Non-Current Assets (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Other Non-Current Assets for 11 consecutive years, with $17733.0 as the latest value for Q1 2025.

  • On a quarterly basis, Other Non-Current Assets changed 0.0% to $17733.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $17733.0, a 0.0% change, with the full-year FY2024 number at $17733.0, down 92.03% from a year prior.
  • Other Non-Current Assets was $17733.0 for Q1 2025 at Regen BioPharma, roughly flat from $17733.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.1 million in Q2 2021 to a low of $17733.0 in Q4 2023.
  • A 5-year average of $173113.6 and a median of $94084.0 in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 5180.78% in 2021, then crashed 92.03% in 2023.
  • Regen BioPharma's Other Non-Current Assets stood at $94084.0 in 2021, then soared by 136.58% to $222580.0 in 2022, then plummeted by 92.03% to $17733.0 in 2023, then changed by 0.0% to $17733.0 in 2024, then changed by 0.0% to $17733.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Other Non-Current Assets are $17733.0 (Q1 2025), $17733.0 (Q4 2024), and $17733.0 (Q3 2024).